



(51) International Patent Classification:

A01H 6/28 (2018.01) A61K 31/352 (2006.01)

A61K 31/202 (2006.01)

(21) International Application Number:

PCT/US2019/059201

(22) International Filing Date:

31 October 2019 (31.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/754,315 01 November 2018 (01.11.2018) US

(71) Applicant: **SCIADONICS, INC.** [US/US]; 1558 Stoneridge Cir., Long Lake, Minnesota 55356 (US).

(72) Inventor: **BERGER, Alvin**; c/o Sciadonics, Inc., 1558 Stoneridge Cir., Long Lake, Minnesota 55356 (US).

(74) Agent: **JONES, John Mitchell**; c/o CASIMIR JONES, S.C., 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND PHYTOCANNABINOID

(57) Abstract: Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMI-FAs) in combination with phytocannabinoid compounds, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinolenic acid and dihomopinolenic acid in combination with phytocannabinoid compounds.



FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND PHYTOCANNABINOIDS

FIELD OF TECHNOLOGY

5 Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with phytocannabinoids and/or terpenes, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinolenic acid and dihomopinolenic acid in combination with phytocannabinoids.

BACKGROUND

 Inflammation is a process by which the body's white blood cells and substances they produce provide protection from infection with foreign organisms, such as bacteria and viruses.

 However, in some diseases, like arthritis, the body's defense system -- the immune system --
15 triggers an inflammatory response when there are no foreign invaders to fight off. In these diseases, called autoimmune diseases, the body's normally protective immune system causes damage to its own tissues. The body responds as if normal tissues are infected or somehow abnormal. Diseases associated with improper inflammation include rheumatoid arthritis, where many joints throughout the entire body are permanently inflamed, psoriasis, a chronic skin disease, and
20 inflammations of the bowel like Crohn's disease or ulcerative colitis, as well as diseases such as atherosclerosis. These diseases are called chronic inflammatory diseases and can last for years or even a lifetime in varying degrees of severity and activity.

 What is needed are new formulations to treat diseases associated with inflammation.

SUMMARY

25 Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with phytocannabinoids and/or terpenes active in cannabinoid pathways, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted
30 fatty acids such as sciadonic acids, juniperonic acid, pinolenic acid and dihomopinolenic acid in combination with phytocannabinoids. Additional embodiments will be apparent to persons skilled in the relevant art based on the teachings contained herein.

 In some preferred embodiments, the present invention provides formulations comprising at least 1% w/w non-methylene interrupted fatty acids (NMIFAs) and a hemp or
35 Cannabis extract. In some preferred embodiments, the hemp or Cannabis extract comprises

cannabidiol (CBD). In some still more preferred embodiments, the hemp or Cannabis extract comprises less than 1% or 0.5% THC.

In some preferred embodiments, the formulations comprise at least 2% w/w, at least 5% w/w, at least 10% w/w, or at least 20% w/w of said NMIFAs. In some embodiments, the composition comprise from 1% to 10% w/w, 1% to 20% w/w, 1% to 30% w/w, 5% to 10% w/w, 5% to 20% w/w, or 5% to 30% w/w of the NMIFAs. In some embodiments, the NMIFAs are selected from the group consisting of sciadonic acid, juniperonic acid, pinolenic acid, dihomopinolenic acid, coniferonic acid (5,9,12,15 18:4) and synthetic fatty acids selected from the group consisting of 1, 11, 14, 17 20:4; 2, 11, 14, 17 20:4; 3, 11, 14 17 20:4; 4, 11, 14 17 20:4; 6, 11,14 17 20:4; 7,11,14 17 20:4; 1, 9, 12, 15 18:4; 2, 9, 12, 15 18:4; 3, 9, 12, 15 18:4; 4, 9, 12, 15 18:4; 5, 9, 12, 15 18:4; 1, 11, 14 20:3; 2, 11, 14 20:3; 3, 11, 14 20:3; 4, 11, 14 20:3; 6, 11,14 20:3; 1, 9, 12 18:3; 2, 9, 12 18:3; 3, 9, 12 18:3; and 4, 9, 12 18:3 fatty acids. In some particularly preferred embodiments, the NMIFA is sciadonic acid. In some embodiments, the NMIFAs are provided as a structured ester, diglyceride, triglyceride or phospholipid wherein at least one ester linkage in said ester, diglyceride, triglyceride or phospholipid contains an NMIFA.

In some preferred embodiments, the formulations comprise at least 2% w/w, at least 5% w/w, at least 10% w/w, at least 20% w/w, or at least 50% w/w of said Cannabis or hemp extract comprising cannabidiol. In some preferred embodiments, the formulations comprise from 1% to 90% w/w, 10% to 90% w/w, 20% to 90% w/w, 30% to 90% w/w, 40% to 90% w/w, or 50% to 90% w/w cannabidiol. In some preferred embodiments, the Cannabis or hemp extract comprising cannabidiol has a cannabidiol concentration of from about 10% to 100% w/w cannabidiol, 20% to 90% w/w cannabidiol, or 20% to 60% w/w cannabidiol.

In some embodiments, the hemp or Cannabis extract comprises at least one phytocannabinoid compound. In some preferred embodiments, the phytocannabinoid compound is selected from the group consisting of Cannabigerol (*E*)-CBG-C₅, Cannabigerol monomethyl ether (*E*)-CBGM-C₅ A, Cannabigerolic acid A (*Z*)-CBGA-C₅ A, Cannabigerovarin (*E*)-CBGV-C₃, Cannabigerolic acid A (*E*)-CBGA-C₅ A, Cannabigerolic acid A monomethyl ether (*E*)-CBGAM-C₅ A and Cannabigerovarinic acid A (*E*)-CBGVA-C₃ A); (±)-Cannabichromene CBC-C₅, (±)-Cannabichromenic acid A CBCA-C₅ A, (±)-Cannabivarichromene, (±)-Cannabichromevarin CBCV-C₃, (±)-Cannabichromevarinic acid A CBCVA-C₃ A); (–)-Cannabidiol CBD-C₅, Cannabidiol monomethyl ether CBDM-C₅, Cannabidiol-C₄ CBD-C₄, (–)-Cannabidivarin CBDV-C₃, Cannabidiorcol CBD-C₁, Cannabidiolic acid CBDA-C₅, Cannabidivarinic acid CBDVA-C₃); Cannabinodiol CBND-C₅, Cannabinodivarin CBND-C₃); Δ⁹-

Tetrahydrocannabinol Δ^9 -THC-C₅, Δ^9 -Tetrahydrocannabinol-C₄ Δ^9 -THC-C₄, Δ^9 -
 Tetrahydrocannabivarin Δ^9 -THCV-C₃, Δ^9 -Tetrahydrocannabiorcol, Δ^9 -THCO-C₁, Δ^9 -
 Tetrahydrocannabinolic acid A Δ^9 -THCA-C₅ A, Δ^9 -Tetrahydrocannabinolic acid B, Δ^9 -
 THCA-C₅ B, Δ^9 -Tetrahydrocannabinolic acid-C₄ A and/or B Δ^9 -THCA-C₄ A and/or B, Δ^9 -
 5 Tetrahydro-cannabivarinic acid A Δ^9 -THCVA-C₃ A, Δ^9 -Tetrahydrocannabiorcolic acid A
 and/or B Δ^9 -THCOA-C₁ A and/or B), (-)- Δ^8 -*trans*-(6a*R*,10a*R*)- Δ^8 -Tetrahydrocannabinol Δ^8 -
 THC-C₅, (-)- Δ^8 -*trans*-(6a*R*,10a*R*)-Tetrahydrocannabinolic acid A Δ^8 -THCA-C₅ A, (-)-
 (6a*S*,10a*R*)- Δ^9 -Tetrahydrocannabinol (-)-*cis*- Δ^9 -THC-C₅); Cannabinol CBN-C₅, Cannabinol-
 C₄ CBN-C₄, Cannabivarin CBN-C₃, Cannabinol-C₂ CBN-C₂, Cannabiorcol CBN-C₁,
 10 Cannabinolic acid A CBNA-C₅ A, Cannabinol methyl ether CBNM-C₅, (-)-(9*R*,10*R*)-*trans*-
 Cannabitrinol (-)-*trans*-CBT-C₅, (+)-(9*S*,10*S*)-Cannabitrinol (+)-*trans*-CBT-C₅, ($\pm$)-
 (9*R*,10*S*/9*S*,10*R*)-); Cannabitrinol ($\pm$)-*cis*-CBT-C₅, (-)-(9*R*,10*R*)-*trans*-10-O-Ethyl-cannabitrinol
 (-)-*trans*-CBT-OEt-C₅, ($\pm$)-(9*R*,10*R*/9*S*,10*S*)-Cannabitrinol-C₃($\pm$)-*trans*-CBT-C₃, 8,9-
 Dihydroxy- $\Delta^{6a(10a)}$ -tetrahydrocannabinol 8,9-Di-OH-CBT-C₅, Cannabidiolic acid A
 15 cannabitrinol ester CBDA-C₅ 9-OH-CBT-C₅ ester, (-)-(6a*R*,9*S*,10*S*,10a*R*)-9,10-Dihydroxy-
 hexahydrocannabinol, Cannabiripsol, Cannabiripsol-C₅, (-)-6a,7,10a-Trihydroxy- Δ^9 -
 tetrahydrocannabinol (-)-Cannabitetrol, 10-Oxo- $\Delta^{6a(10a)}$ -tetrahydrocannabinol OTHC);
 (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoin CBE-C₅, (5a*S*,6*S*,9*R*,9a*R*)-C₃-Cannabielsoin CBE-C₃,
 (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoic acid A CBEA-C₅ A, (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoic acid B
 20 CBEA-C₅ B; (5a*S*,6*S*,9*R*,9a*R*)-C₃-Cannabielsoic acid B CBEA-C₃ B, Cannabiglendol-C₃ OH-
 iso-HHCV-C₃, Dehydrocannabifuran DCBF-C₅, Cannabifuran CBF-C₅), (-)- Δ^7 -*trans*-
 (1*R*,3*R*,6*R*)-Isotetrahydrocannabinol, ($\pm$)- Δ^7 -1,2-*cis*-(1*R*,3*R*,6*S*/1*S*,3*S*,6*R*)-
 Isotetrahydrocannabivarin, (-)- Δ^7 -*trans*-(1*R*,3*R*,6*R*)-Isotetrahydrocannabivarin); ($\pm$)-
 (1a*S*,3a*R*,8b*R*,8c*R*)-Cannabicyclol CBL-C₅, ($\pm$)-(1a*S*,3a*R*,8b*R*,8c*R*)-Cannabicyclic acid A
 25 CBLA-C₅ A, ($\pm$)-(1a*S*,3a*R*,8b*R*,8c*R*)-Cannabicyclovarin CBLV-C₃; Cannabicitran CBT-C₅);
 Cannabichromanone CBCN-C₅, Cannabichromanone-C₃ CBCN-C₃, and
 Cannabicumaronone CBCON-C₅).

In some preferred embodiments, the formulations comprise at least 1% w/w, at least 2%
 w/w, at least 5% w/w, or at least 10% w/w of said at least one phytocannabinoid compound. In some
 30 preferred embodiments, the formulations comprise from 0.1% to 10% w/w, 1% to 10% w/w, 0.1% to
 5% w/w, 1% to 5% w/w, 1% to 20% w/w, 5% to 10% w/w, 5% to 20% w/w, or 10% to 20% w/w of
 said at least one phytocannabinoid compound.

In some preferred embodiments, the hemp or Cannabis extract comprises at least one
 terpenoid compound. In some preferred embodiments, the at least one terpenoid compound is

selected from the group consisting of Alloaromadendrene, allyl hexanoate, benzaldehyde, (Z)- α -cis-bergamotene, (Z)- α -trans-bergamotene, β -bisabolol, epi- α -bisabolol, β -bisabolene, borneol (camphol), *cis*- γ -bisabolene, borneol acetate (bornyl acetate), α -cadinene, camphene, camphor, *cis*-carveol, caryophyllene (β -caryophyllene), α -humulene (α -caryophyllene), γ -cadinene, Δ -3-carene, caryophyllene oxide, 1,8-cineole, citral A, citral B, cinnamaldehyde, α -copaene (aglaiene), γ -curcumene, β -cymene, β -elemene, γ -elemene, ethyl decdienoate, ethyl maltol, ethyl propionate, ethylvanillin, eucalyptol, α -eudesmol, β -eudesmol, γ -eudesmol, eugenol, *cis*- β -farnesene ((Z)- β -farnesene), *trans*- α -farnesene, *trans*- β -farnesene, *trans*- γ -bisabolene, fenchone, fenchol (norbornanol, β -fenchol), geraniol, α -guaiene, guaiol, methyl anthranilate, methyl salicylate, 2-methyl-4-heptanone, 3-methyl-4-heptanone, hexyl acetate, ipsdienol, isoamyl acetate, lemenol, limonene, d-limonene (limonene), linolool (linalyl alcohol, β -linolool), α -longipinene, menthol, γ -muurolene, myrcene (β -myrcene), nerolidol, *trans*-nerolidol, nerol, β -ocimene (*cis*-ocimene), octyl acetate, α -phellandrene, phytol, α -pinene (2-pinene), β -pinene, pulegone, sabinene, *cis*-sabinene hydrate (*cis*-thujanol), β -selinene, α -selinene, γ -terpinene, terpinolene (isoterpine), terpineol (α terpineol), terpineol-4-ol, α -terpinene (terpilene), α -thujene (origanene), vanillin, viridiflorene (ledene), and α -ylange.

In some preferred embodiments, the formulations comprise at least 0.1% w/w, at least 1% w/w, at least 2% w/w, at least 5% w/w, or at least 10% w/w of said at least one terpenoid compound. In some preferred embodiments, the formulations comprise from 0.1% to 10% w/w, 1% to 10% w/w, 0.1% to 5% w/w, 1% to 5% w/w, 1% to 20% w/w, 5% to 10% w/w, 5% to 20% w/w, or 10% to 20% w/w of said at least one terpenoid compound.

In some preferred embodiments, the present invention provides an oral delivery vehicle comprising a formulation as described above. In some preferred embodiments, the oral delivery vehicle is selected from the group consisting of a capsule, gel capsule, soft gel capsule and syrup. In some preferred embodiments, the oral delivery vehicle further comprises a flavoring agent and/or antioxidant not naturally occurring with said NMIFA and/or said at least one phytocannabinoid compound.

In some preferred embodiments, the present invention provides methods of reducing or treating inflammation in a subject in thereof comprising administering an effective amount of a formulation or oral delivery vehicle as defined above. In some preferred embodiments, the present invention provides a formulation or oral delivery vehicle as defined above for use to reduce or treat inflammation in a subject in need thereof. In some preferred embodiments, the inflammation is caused by or associated with a disease or condition selected from the group consisting of restenosis, arteriosclerosis, coronary heart disease, thrombosis, myocardial infarction, stroke, hypertension, fatty

liver, diabetes, hyperglycemia, hyperinsulinemia, and stenosis, rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), inflammatory bowel diseases and colitis (e.g., Crohn's colitis), nephritis, various inflammatory skin disorders (e.g. psoriasis, atopic dermatitis and food allergy) and acute and chronic allograft rejection after organ transplantation.

In some preferred embodiments, the present invention provides methods of reducing or treating pain in a subject in thereof comprising administering an effective amount of a formulation or oral delivery vehicle as defined above. In some preferred embodiments, the present invention provides a formulation or oral delivery vehicle as defined above for use to reduce or treat pain in a subject in need thereof.

DETAILED DESCRIPTION

Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with cannabinoid compounds and/or terpenes, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinolenic acid and dihomopinolenic acid in combination with cannabinoid compounds and/or terpenes.

This technology is described below, wherein the section headings are for organizational purposes only and are not to be construed as limiting the described subject matter in any way.

In this detailed description of the various embodiments, for purposes of explanation, numerous specific details are set forth to provide a thorough understanding of the embodiments disclosed. One skilled in the art will appreciate, however, that these various embodiments may be practiced with or without these specific details. In other instances, structures and devices are shown in block diagram form. Furthermore, one skilled in the art can readily appreciate that the specific sequences in which methods are presented and performed are illustrative and it is contemplated that the sequences can be varied and still remain within the spirit and scope of the various embodiments disclosed herein.

All literature and similar materials cited in this application, including but not limited to, patents, patent applications, articles, books, treatises, and internet web pages are expressly incorporated by reference in their entirety for any purpose. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which the various embodiments described herein belongs. When definitions of terms in incorporated references appear to differ from the definitions provided in the present teachings, the definition provided in the present teachings shall control.

Definitions

To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.

Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the technology may be readily combined, without departing from the scope or spirit of the technology.

In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”

As used herein, “feeding” refers to providing a substance, compound, composition, etc. to a living organism. For example, the substance, compound, composition, etc. may be an energy source, a carbon source, a nutrient, or a source of other elements, molecules, and/or precursors of biological molecules that are used by the living organism and/or are metabolized (e.g., catabolized, anabolized) by the living organism. The substance, compound, composition, etc. is not necessarily a substance, compound, composition, etc. that the living organism encounters in its native milieu, but may be a synthetic substance, compound, composition, etc. or a natural substance, compound, composition, etc. that is nevertheless used by the living organism for metabolism. The substance, compound, composition, etc. may be added to a culture medium or a substrate in which or on which the living organism lives and/or grows.

As used herein, “active” or “activity” refers to native or naturally occurring biological and/or immunological activity.

As used herein, the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g., a human with a disease such as obesity, diabetes, or insulin resistance).

As used herein, the term “individual” refers to vertebrates, particularly members of the mammalian species. The term includes but is not limited to domestic animals, sports animals, primates, and humans.

As used herein, the term “effective amount” refers to the amount of a composition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.

As used herein, the term “administration” refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment to a subject. Exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (transdermal, topical), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.), and the like.

As used herein, the term “co-administration” refers to the administration of at least two agents or therapies to a subject. In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy. Those of skill in the art understand that the formulations and/or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent.

As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for therapeutic use.

The terms “pharmaceutically acceptable” or “pharmacologically acceptable”, as used herein, refer to compositions that do not substantially produce adverse reactions, e.g., toxic, allergic, or immunological reactions, when administered to a subject.

As used herein, the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a disease or disorder through introducing in any way a therapeutic composition of the present technology into or onto the body of a subject. “Treatment” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

As used herein, the term “sample” is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like. Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples. Such examples are not however to be construed as limiting the sample types applicable to the present technology.

As used herein the term “Cannabis” is used to refer to plants of the genus *Cannabis*, including *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis*.

As used herein, the term “cannabinoid” refers to a chemical compound that shows direct or indirect activity at a cannabinoid receptor. There are two main cannabinoid receptors, CB₁ and CB₂. Other receptors that research suggests have cannabinoid activity include the GPR55 and GPR18 receptors. The term “phytocannabinoid” refers to
 5 cannabinoids that occur in a plant species or are derived from cannabinoids occurring in a plant species.

Embodiments of the technology

Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with phytocannabinoids, and particularly, but not
 10 exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinolenic acid and dihomopinolenic acid in combination with phytocannabinoids. Below, sources of NMIFAs, phytocannabinoid compounds, compositions and formulations comprising these agents, and methods for making the
 15 compositions and formulations and uses of the compositions and formulations are described. The present invention contemplates that the combined administration of the agents provides a synergistic action in reducing inflammation and in treating diseases associated with inflammation and also in treating pain.

20 Non-methylene-interrupted fatty acids

The term non-methylene-interrupted fatty acid, the acronym for which is NMIFA, refers to a fatty acid with a series of double bonds in which at least one adjacent pair of double bonds is separated by at least two carbon atoms, i.e., by a group other than a single methylene group. Examples of NMIFA include, but are not limited to, 5,11,14-eicosatrienoic acid (sciadonic acid);
 25 5,9,12-cis-octadecatrienoic acid (pinolenic acid); and 5,11,14,17-eicosatetraenoic acid (juniperonic acid). Preferred NMIFAs have the following formula, wherein the NMIFA is an acid, a salt or an ester, and R₁ is a C₁-C₅ alkyl group and R₂ is a C₂-C₆ alkyl group, may be advantageously used for the preparation of a composition intended to modulate the metabolism of lipids in superficial mammalian tissues.



Particularly preferred NMIFAs are those in which R₁ is a C₃ alkyl group and R₂ is a C₂-C₆ alkyl group, or in which R₂ is a C₄ alkyl group and R₁ is a C₁-C₅ alkyl group. The most preferred is

that in which R1 is an n-propyl group and R2 is an n-butyl group (5,11,14-eicosatrienoic acid, also called 20:3(5,11,14)). The NMIFAs may be preferably provided as triglycerides, phospholipids, fatty acids ester, free fatty acids or combinations thereof.

Sciadonic acid (5,11,14-eicosatrienoic acid, 20:3 Δ 5,11,14) is a polyunsaturated fatty acid containing non-methylene-interrupted double bonds, such as a Δ 5-ethylenic bond. Sciadonic acid is often found in gymnosperms, in seed oils, leaves, and wood. It is also found in a few angiosperms, especially in seed oils. Sciadonic acid has several biological activities, including lowering triglyceride and cholesterol levels, reducing reperfusion injury, modifying autoimmune response, having cannabimimetic effect, treatment of skin disease, and treatment of sensitive or dry skin. WO 95/17987 (The Regents of the University of California) shows that broad class of NMIFAs, including 5,11,14-eicosatrienoic acid, may be used in an effective amount for suppressing autoimmune diseases in general, for example rheumatoid arthritis, lupus erythematosis, multiple sclerosis, myasthenia gravis, and about 30 other diseases currently known. NMIFAs, including 5,11,14-eicosatrienoic acid, are further described in US Pat. Nos. 5,456,912 and 6,280,755 as well as US Publ. No. 20120156171, each of which is incorporated herein by reference in its entirety.

Pinolenic acid ((5Z,9Z,12Z)-octadeca-5,9,12-trienoic acid; *all-cis*-5,9,12-18:3) is a fatty acid contained in Siberian Pine nuts, Korean Pine nuts and the seeds of other pines (*Pinus* species). The highest percentage of pinolenic acid is found in Siberian pine nuts and the oil produced from them. JP 61 058 536 (Nippon Oil) discloses a method for purifying pine nut oil containing at least 10% by weight of 5,9,12-cis-octadecatrienoic acid which exhibits a curative effect against arterial hypertension. WO 96 05 164 (Broadben Nominees Pty) discloses an anti-inflammatory preparation comprising a purified active fraction, for example 5,11,14,17-eicosatetraenoic acid, isolated from a lipid extract of *Perna canaliculus* or *Mytilus edulis*. Dihomopinolenic acid also finds use in the compositions of the present invention.

Some of the NMIFAs of the invention are naturally occurring substances. Others may be synthesized according to well-known published methodology (see for example Evans et al., *Chem. Phys. Lipids*, 38, 327-342, 1995).

For example, 20:3(5,11,14) is a naturally occurring substance which generally occurs as one fatty acid in a mixture of fatty acids. This NMIFA is found in a wide variety of plants as minor or major fraction of the total fatty acid composition. Both the extraction of the mixture of fatty acid from their natural sources and the extraction of the 20:3(5,11,14) from the resulting fatty acids can be achieved by conventional extraction and purification methods well known among those skilled in the art.

The natural sources of fatty acids containing 20:3(5,11,14) are primarily plant seeds, and prominent among these are conifers and ornamental shrubs. The seed oils from these plants are similar to normal edible oils, containing largely oleic, linoleic and linolenic acids, but also containing

useful amounts of NMIFAs. Table 1 lists examples of seeds whose lipid contents contain significant amounts of 20:3(5,11,14).

Source	% of 20:3 (5,11,14) among total fatty acids	Source	% of 20:3 (5,11,14) among total fatty acids
<i>Juniperus</i> <i>virginiana</i>	14.8	<i>Sciadopitys</i> <i>verticillata</i>	15
<i>Platycladus</i> <i>orientalis</i>	3	<i>Cedrus</i> <i>palustris</i>	23
<i>Juniperus</i> <i>chinensis</i>	12.3	<i>Calamus</i> <i>rhomboides</i>	14
<i>Torreya</i> <i>nucifera</i>	7	<i>Monarda</i> <i>alpinia*</i>	7
<i>Podocarpus</i> <i>nagi</i>	24	<i>Ephedra</i> <i>campylopoda</i>	22
<i>Anemone</i>	10	<i>Anemone</i>	6

Source	% of 20:3 (5,11,14) among total fatty acids	Source	% of 20:3 (5,11,14) among total fatty acids
<i>Rhus</i> <i>copallina</i>	6	<i>Levinsii</i> <i>Erantia</i>	6
<i>racemosa</i>		<i>hyemalis</i>	
<i>Ginkgo</i> <i>biloba</i>	2.3	<i>Pinus</i> <i>silvestris</i>	7

*see the Japanese patent JP5276964 (Sumitomo LTD)

Purification of 20:3(5,11,14) may be in particular achieved by (1) choosing a starting seed source high in total fat content and 20:3(5,11,14) content but not containing other contaminating trienes, in particular alpha-linolenic acid (18:3n-3) and gamma-linolenic acid (18:3n-6) (Podocarpus nagi, Table 1, is such an example); (2) extracting the lipids with isopropanol and chloroform according to the method of Nichols (Biochim. Biophys Acta 70: 417, 1963); (3) conventional degumming and decoloring methods; (4) preparing methyl esters with 2% methanolic sulfuric acid according to the method of Christie (p. 52-53, in Lipid Analysis, Pergamon Press, Oxford, 1982); (5) eluting 20:3(5,11,14) methyl ester from a silver nitrate impregnated acid-washed Florisil column with a hexane:ether mixture ranging from 9:1 to 8:2 (volume/volume) according to Carroll, J. Am. Oil Chem. Soc. 40: 413, 1963; Wilner, Chem. Ind (Lond) October, 30: 1839, 1965; Merck ChromNews 4(1): 1995; Anderson, J. Lipid Res. 6: 577, 1965; and Teshima, Bull. Jap. Soc. Scien. Fish. 44: 927, 1978); (6) removing contaminating silver ions by the method of Akesson (Eur. J. Biochem. 9:463, 1969); and (7) optionally converting the methyl ester back to the free acid form by saponification in 1 M potassium hydroxide in 95% ethanol according to Christie (p. 51-52, in Lipid Analysis, Pergamon Press, Oxford, 1982).

20:4 fatty acids and analogs are utilized in the present invention. In referred embodiments, the 20:4 fatty acids have a non-methylene-interrupted bond system. Natural sources of 20:4 fatty acids and analogs, especially juniperonic acid (5, 11, 14, 17 20:4) include juniper berries from various *Juniperus spp.*, including, but not limited to: *J. communis*, *J. chinensis*, *J. conferta*, *J. rigida*, *J. brevifolia*, *J. cedrus*, *J. deltoides*, *J. formosana*, *J. hutchensis*, *J. navicularis*, *J. oxycedrus*, *J. macrocarpa*, *J. drupacea*, *J. convallium*, *J. excels*, *J. foetidissima*, *J. indica*, *J. komarovii*, *J. phoenicea*, *J. pingii*, *J. procera*, *J. procumbens*, *J. pseudosabina*, *J. recurve*, *J. sabina*, *J. saltuaria*, *J. semiglobosa*, *J. squamata*, *J. thurifera*, *J. tibetica*, *J. wallichiana*, *J. angosturana*, *J. ashei*, *J. arizonica*, *J. barbadensis*, *J. bermudiana*, *J. blancoi*, *J. californica*, *J. coahuilensis*, *J. comitana*, *J. deppeana*, *J. durangensis*, *J. flaccida*, *J. gamboana*, *J. horizontalis*, *J. jaliscana*, *J. monosperma*, *J. monticola*, *J. occidentalis*, *J. osteosperma*, *J. pinchotii*, *J. saltillensis*, *J. scopulorum*, *J. standleyi* and *J. virginiana*.

In some preferred embodiments, an oil (juniper berry oil) is extracted from juniper berry powder, most preferably a powder made from *J. communis* or *J. chinensis* berries. In some especially preferred embodiments, the juniper berry oil is extracted from the waste or residue from juniper berry oil processing for essential oils, i.e., juniper berries that have been previously subjected to steam distillation, or from juniper berries that have been used in the production of gin or other flavored spirits. For sources of juniper berry waste or residues, see, e.g., Slankovic, M. and Randjelovic, M. Hem. Ind. 1980, 34, 355-377; Dyr, J. and Uher, J. Czech. Pat. 134,003, 1970; Grog, I. Kern. Ind. 1983, 32, 575-578; and Veljkovic et al., Enz. Microb. Technol. 1990, 12, 706-709.

Juniper berries have been previously extracted in for the essential oil market by steam distillation or soaking the berries in vegetable. This extracts aromatic components, but not triglycerides or other fatty acid containing components. In contrast, in preferred embodiments of the present invention, juniper oil comprising or consisting essentially of triglycerides is extracted a juniper feedstock (e.g., juniper berries, juniper berry powder, steam-distilled juniper berries or juniper berry waste (e.g., juniper berry residue from gin or other spirit manufacturing). In some embodiments, the outer coat of the juniper berries in the juniper feedstock is removed by treatment with acid. In some embodiments, oil is extracted from the juniper feedstock by cold pressing. In other embodiments, the oil is extracted from the juniper feedstock by solvent extraction. Suitable solvents include food grade solvents such as n-hexane and cyclohexane, liquid propane, isopropanol, acetone, ethyl acetate, ethanol and combination thereof. In other embodiments, super critical fluid extraction using carbon dioxide is utilized to extract oil from the juniper feedstock. Juniper oils can contain certain irritants, hence in some embodiments, conventional processing (washing, bleaching, deodorizing) are employed.

In some preferred embodiments, the extracted oil comprises or consists essentially of triglycerides. The oil obtained from the extraction is generally characterized as having a ratio of juniperonic acid to sciadonic acid of from about 1:5 to 5:1, 1:2.5 to 2.5:1, 1:2 to 2:1, 1:1.5 to 1.5:1,


1:1 to 3:1, 1:5 to 2.5:1, 1:3 to 1:1 or 1:1 to 1:1.5. In some embodiments, the weight percent of juniperonic acid expressed as grams per 100 grams fatty acids in the oil is from about 5% to 20%, 5% to 15%, 8% to 15%, or 3% to 10%. In some embodiments, the weight percent of sciadonic acid expressed as grams per 100 grams fatty acids in the oil is from about 5% to 20%, 5% to 15%, 8% to 20%, or 3% to 10%.

Purification of juniperonic acid may be in particular achieved by (1) choosing a starting juniper feedstock as described above (2) extracting the lipids with a suitable solvent as described above; (3) conventional degumming and decoloring methods; (4) preparing ethyl esters; (5) separating the juniperonic acid by molecular distillation of the ethyl esters or lower molecular weight, and (7) optionally converting the ethyl ester back to the free acid form.


In some embodiments, the juniper oil is formulated for oral delivery, for example by encapsulation in a soft gel capsule or as described in more detail below. In some embodiments, the juniper oil is protected from oxidation by formulating the juniper oil with an antioxidant. Suitable antioxidants include, but are not limited to, ascorbic acid and tocopherol.

Phytocannabinoid compounds


In preferred embodiments, the present invention provides compositions and formulation comprising an NMIFA as described as above in combination with a phytocannabinoids and/or terpenes. In some preferred embodiments, the phytocannabinoids and/or terpenes are derived or obtained from plant parts of plants of the genus *Cannabis*, including *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis*. Examples of phytocannabinoid compounds include, but are not limited to, Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN), Cannabigerol (CBG), Cannabichromene (CBC), Cannabicyclol (CBL), Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV), Cannabigerol Monomethyl Ether (CBGM). Examples of structures of cannabinoids include, but are not limited to:




Cannabigerol monomethyl ether Cannabigerolic acid A



Cannabigerovarin




Cannabigerolic acid A
(*E*)-CBGA-C₅ A



Cannabigerolic acid A
monomethyl ether
(*E*)-CBGAM-C₅ A

5



Cannabigerovarinic acid A
(*E*)-CBGVA-C₃ A




(±)-Cannabichromene
CBC-C₅




(±)-Cannabichromenic acid A
CBCA-C₅ A

10



(±)-Cannabivarichromene,
(±)-Cannabichromevarin
CBCV-C₃




(±)-Cannabichromevarinic
acid A
CBCVA-C₃ A



(-)-Cannabidiol
CBD-C₅

15



Cannabidiol
monomethyl ether
CBDM-C₅



Cannabidiol-C₄
CBD-C₄




(-)-Cannabidivarin
CBDV-C₃


20



Cannabidiol
CBD-C₁



Cannabidiolic acid
CBDA-C₅



Cannabidivarinic acid
CBDVA-C₃

5



Cannabidiol
CBND-C₅




Cannabinodivarin
CBND-C₃




Δ^9 -Tetrahydrocannabinol
 Δ^9 -THC-C₅

10



Δ^9 -Tetrahydrocannabinol-C₄
 Δ^9 -THC-C₄




Δ^9 -Tetrahydrocannabinol-C₃
 Δ^9 -THCV-C₃




Δ^9 -Tetrahydrocannabinol-C₁
 Δ^9 -THCO-C₁


15



Δ^9 -Tetrahydrocannabinolic acid A
 Δ^9 -THCA-C₅ A






Δ^9 -Tetrahydrocannabinolic acid B
 Δ^9 -THCA-C₅ B




Δ^9 -Tetrahydrocannabinolic acid-C₄
A and/or B
 Δ^9 -THCA-C₄ A and/or B

20



Δ^9 -Tetrahydro-
cannabivarinic acid A

Δ^9 -THCVA-C₃ A



(-)- Δ^8 -*trans*-(6a*R*,10a*R*)-
Tetrahydrocannabinolic
acid A

Δ^8 -THCA-C₅ A

Δ^9 -Tetrahydro-
cannabiorcolic acid
and/or B

Δ^9 -THCOA-C₁ A and/or B




(-)-(6a*S*,10a*R*)- Δ^9 -
Tetrahydrocannabinol
(-)-*cis*- Δ^9 -THC-C₅

(-)- Δ^8 -*trans*-(6a*R*,10a*R*)-


Δ^8 -Tetrahydrocannabinol

Δ^8 -THC-C₅




Cannabinol

CBN-C₅




Cannabinol-C₄

CBN-C₄




Cannabivarin

CBN-C₃




Cannabinol-C₂

CBN-C₂




Cannabiorcol

CBN-C₁




Cannabinolic acid A

CBNA-C₅ A




Cannabinol methyl ether

CBNM-C₅




(-)-(9*R*,10*R*)-*trans*-
Cannabitriol

(-)-*trans*-CBT-C₅




(+)-(9*S*,10*S*)-Cannabitriol
(+)-*trans*-CBT-C₅




(±)-(9*R*,10*S*/9*S*,10*R*)-
Cannabitriol


(±)-*cis*-CBT-C₅



(-)-(9*R*,10*R*)-*trans*-
10-O-Ethyl-cannabitrinol
(-)-*trans*-CBT-OEt-C₅




(±)-(9*R*,10*R*/9*S*,10*S*)-
Cannabitrinol-C₃
(±)-*trans*-CBT-C₃




8,9-Dihydroxy-Δ^{6a(10a)}-
tetrahydrocannabinol
8,9-Di-OH-CBT-C₅


5



Cannabidiolic acid A
cannabitrinol ester
CBDA-C₅ 9-OH-CBT-C₅ ester




(-)-(6*aR*,9*S*,10*S*,10*aR*)-
9,10-Dihydroxy-
hexahydrocannabinol,
Cannabiripsol
Cannabiripsol-C₅



(-)-6*a*,7,10*a*-Trihydroxy-
Δ⁹-tetrahydrocannabinol
(-)-Cannabitetrol

10

15



10-Oxo-Δ^{6a(10a)}-
tetrahydrocannabinol
OTHC



(5*aS*,6*S*,9*R*,9*aR*)-
Cannabielsoin
CBE-C₅



(5*aS*,6*S*,9*R*,9*aR*)-
C₃-Cannabielsoin
CBE-C₃

20



(5a*S*,6*S*,9*R*,9a*R*)-



Cannabielsoic acid A

CBEA-C₅ A(5a*S*,6*S*,9*R*,9a*R*)-


Cannabielsoic acid B

CBEA-C₅ B(5a*S*,6*S*,9*R*,9a*R*)-C₃-Cannabielsoic acid B**CBEA-C₃ B**

5

Cannabiglendol-C₃**OH-iso-HHCV-C₃**

Dehydrocannabifuran

DCBF-C₅

Cannabifuran

CBF-C₅

10

(-)-Δ⁷-*trans*-(1*R*,3*R*,6*R*)-

Isotetrahydrocannabinol

(±)-Δ⁷-1,2-*cis*-(1*R*,3*R*,6*S*/1*S*,3*S*,6*R*)-

Isotetrahydro-

Cannabivarin

(-)-Δ⁷-*trans*-(1*R*,3*R*,6*R*)-

Isotetrahydrocannabivarin


15

(±)-(1a*S*,3a*R*,8b*R*,8c*R*)-

Cannabicyclol

CBL-C₅(±)-(1a*S*,3a*R*,8b*R*,8c*R*)-


Cannabicyclic acid A

CBLA-C₅ A(±)-(1a*S*,3a*R*,8b*R*,8c*R*)-


Cannabicyclovarin

CBLV-C₃


20



Cannabicitran

CBT-C₅

Cannabichromanone

CBCN-C₅Cannabichromanone-C₃**CBCN-C₃**

25



5

Cannabichromanol

CBCN-C₅


In some embodiments, the formulations and compositions comprise one or more
 10 terpenoid compounds, preferably one or more terpenes derived *Cannabis*. The terpenoids
 may be included alone or in combination with one or more of the phytocannabinoids
 compounds. The terpenoids are preferably selected from one or more of alloaromadendrene,
 allyl hexanoate, benzaldehyde, (Z)- α -cis-bergamotene, (Z)- α -trans-bergamotene, β -bisabolol,
 epi- α -bisabolol, β -bisabolene, borneol (camphol), *cis*- γ -bisabolene, borneol acetate (bornyl
 15 acetate), α -cadinene, camphene, camphor, *cis*-carveol, caryophyllene (β -caryophyllene), α -
 humulene (α -caryophyllene), γ -cadinene, Δ -3-carene, caryophyllene oxide, 1,8-cineole, citral
 A, citral B, cinnamaldehyde, α -copaene (aglaione), γ -curcumen, β -cymene, β -elemene, γ -
 elemene, ethyl decadienoate, ethyl maltol, ethyl propionate, ethylvanillin, eucalyptol, α -
 eudesmol, β -eudesmol, γ -eudesmol, eugenol, *cis*- β -farnesene ((Z)- β -farnesene), *trans*- α -
 20 farnesene, *trans*- β -farnesene, *trans*- γ bisabolene, fenchone, fenchol (norbornanol, β -fenchol),
 geraniol, α -guaiane, guaial, methyl anthranilate, methyl salicylate, 2-methyl-4-heptanone, 3-
 methyl-4-heptanone, hexyl acetate, ipsdienol, isoamyl acetate, lemenol, limonene, d-
 limonene (limonene), linolool (linalyl alcohol, β -linolool), α -longipinene, menthol, γ -
 muurolene, myrcene (β -myrcene), nerolidol, *trans*-nerolidol, nerol, β -ocimene (*cis*-ocimene),
 25 octyl acetate, α -phellandrene, phytol, α -pinene (2-pinene), β -pinene, pulegone, sabinene, *cis*-
 sabinene hydrate (*cis*-thujanol), β -selinene, α -selinene, γ -terpinene, terpinolene (isoterpine),
 terpineol (α terpineol), terpineol-4-ol, α -terpinene (terpilene), α -thujene (organene), vanillin,
 viridiflorene (ledene), and α -ylange

30 Bioactive Compositions and Formulations

The present invention provides bioactive compositions and formulations comprising one or
 more bioactive NMIFAs, in combination with phytocannabinoid compounds such as CBD.

In preferred embodiments, the compositions and formulations of the present invention have a content of at least 1%, 2%, 5%, 10%, 20%, 30% or 40% NMIFAs on a w/w basis (total weight of NMIFA/total weight of the formulation), or from about 1% to 40%, 2% to 40%, 5% to 40%, 10% to 40%, 1% to 30%, 2% to 30%, 5% to 30%, 10% to 30%, 1% to 20%, 2% to 20%, 5% to 20%, or 10% to 20% NMIFAs on w/w basis. Preferred NMIFAs include, but are not limited to, sciadonic acid, juniperonic acid, pinolenic acid, dihomopinolenic acid, coniferonic acid (5,9,12,15 18:4), and synthetic fatty acids selected from the group consisting of 1, 11, 14, 17 20:4; 2, 11, 14, 17 20:4; 3, 11, 14 17 20:4; 4, 11, 14 17 20:4; 6, 11,14 17 20:4; 7,11,14 17 20:4; 1, 9, 12, 15 18:4; 2, 9, 12, 15 18:4; 3, 9, 12, 15 18:4; 4, 9, 12, 15 18:4; 5, 9, 12, 15 18:4; 1, 11, 14 20:3; 2, 11, 14 20:3; 3, 11, 14 20:3; 4, 11, 14 20:3; 6, 11,14 20:3; 1, 9, 12 18:3; 2, 9, 12 18:3; 3, 9, 12 18:3; and 4, 9, 12 18:3 fatty acids.

In some preferred embodiments, the compositions and formulations of the present invention further comprise a cannabis or hemp extract comprising cannabidiol (CBD):



In some embodiments, the compositions and formulations of the present invention comprise at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of a cannabis or hemp extract on a w/w basis (total weight of cannabis or hemp extract/total weight of the formulation) or from about 1% to 95%, 2% to 90%, 5% to 80%, 10% to 90%, 20% to 90%, 30% to 90%, 40% to 90%, 50% to 90%, 60% to 90% cannabis or hemp extract on w/w basis. The weight percent of CBD in the cannabis or hemp extract may vary from 1% to 100% and is preferably from 25% to 90% of the extract.

In other embodiments, the compositions and formulations of the present invention may be defined by the weight percent of CBD in the composition or formulation in combination with the weight percentage of the NMIFA of the formulation. For example, in some preferred embodiments, the compositions and formulations of the present invention comprise at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of CBD on a w/w basis (total weight of CBD/total weight of the formulation) or from about 1% to 95%, 2% to 90%, 5% to 80%, 10% to 90%, 20% to 90%, 30% to 90%, 40% to 90%, 50% to 90%, 60% to 90% CBD on w/w basis, and at least 1%, 2%, 5%, 10%, 20%, 30% or 40% NMIFAs on a w/w basis (total weight of NMIFA/total weight of the formulation), or from about 1% to 40%, 2% to 40%, 5% to 40%, 10% to 40%, 1% to 30%, 2% to 30%, 5% to 30%, 10% to 30%, 1% to 20%, 2% to 20%, 5% to 20%, or 10% to 20% NMIFAs on w/w basis. It will be recognized the total weight percent of CBD and NMIFA in the extract will not exceed 100% w/w. In some preferred embodiments, the cannabis or hemp extract (or CBD concentrate) contains less than 1%, 0.5% or 0.1% THC on a w/w basis. In some embodiments,

oral delivery vehicles of the present invention provides from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg CBD and from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg NMIFA.

In some other embodiments, the compositions and formulations of the present invention
 5 comprise at least one phytocannabinoid compound in addition to the NMIFAs and/or CBD described above. Preferred phytocannabinoid compounds include, but are not limited to, Cannabigerol (*E*)-CBG-C₅, Cannabigerol monomethyl ether (*E*)-CBGM-C₅ A, Cannabigerolic acid A (*Z*)-CBGA-C₅ A, Cannabigerovaric acid (*E*)-CBGV-C₃, Cannabigerolic acid A (*E*)-CBGA-C₅ A, Cannabigerolic acid A monomethyl ether (*E*)-CBGAM-C₅ A and Cannabigerovarinic acid A
 10 (*E*)-CBGVA-C₃ A); (±)-Cannabichromene CBC-C₅, (±)-Cannabichromenic acid A CBCA-C₅ A, (±)-Cannabivarichromene, (±)-Cannabichromevarin CBCV-C₃, (±)-Cannabichromevarinic acid A CBCVA-C₃ A); (-)-Cannabidiol CBD-C₅, Cannabidiol monomethyl ether CBDM-C₅, Cannabidiol-C₄ CBD-C₄, (-)-Cannabidivarin CBDV-C₃, Cannabidiorcol CBD-C₁, Cannabidiolic acid CBDA-C₅, Cannabidivarinic acid CBDVA-C₃); Cannabinodiol CBND-
 15 C₅, Cannabinodivarin CBND-C₃); Δ⁹-Tetrahydrocannabinol Δ⁹-THC-C₅, Δ⁹-Tetrahydrocannabinol-C₄ Δ⁹-THC-C₄, Δ⁹-Tetrahydrocannabivarin Δ⁹-THCV-C₃, Δ⁹-Tetrahydrocannabiorcol, Δ⁹-THCO-C₁, Δ⁹-Tetrahydrocannabinolic acid A Δ⁹-THCA-C₅ A, Δ⁹-Tetrahydrocannabinolic acid B, Δ⁹-THCA-C₅ B, Δ⁹-Tetrahydrocannabinolic acid-C₄ A and/or B Δ⁹-THCA-C₄ A and/or B, Δ⁹-Tetrahydrocannabivarinic acid A Δ⁹-THCVA-C₃ A,
 20 Δ⁹-Tetrahydrocannabiorcolic acid A and/or B Δ⁹-THCOA-C₁ A and/or B), (-)-Δ⁸-*trans*-(6a*R*,10a*R*)-Δ⁸-Tetrahydrocannabinol Δ⁸-THC-C₅, (-)-Δ⁸-*trans*-(6a*R*,10a*R*)-Tetrahydrocannabinolic acid A Δ⁸-THCA-C₅ A, (-)-(6a*S*,10a*R*)-Δ⁹-Tetrahydrocannabinol (-)-*cis*-Δ⁹-THC-C₅); Cannabinol CBN-C₅, Cannabinol-C₄ CBN-C₄, Cannabivarin CBN-C₃, Cannabinol-C₂ CBN-C₂, Cannabiorcol CBN-C₁, Cannabinolic acid A CBNA-C₅ A,
 25 Cannabinol methyl ether CBNM-C₅, (-)-(9*R*,10*R*)-*trans*-Cannabitrinol (-)-*trans*-CBT-C₅, (+)-(9*S*,10*S*)-Cannabitrinol (+)-*trans*-CBT-C₅, (±)-(9*R*,10*S*/9*S*,10*R*)-); Cannabitrinol (±)-*cis*-CBT-C₅, (-)-(9*R*,10*R*)-*trans*-10-O-Ethyl-cannabitrinol (-)-*trans*-CBT-OEt-C₅, (±)-(9*R*,10*R*/9*S*,10*S*)-Cannabitrinol-C₃(±)-*trans*-CBT-C₃, 8,9-Dihydroxy-Δ^{6a(10a)}-tetrahydrocannabinol 8,9-Di-OH-CBT-C₅, Cannabidiolic acid A cannabitrinol ester CBDA-C₅ 9-OH-CBT-C₅ ester, (-)-
 30 (6a*R*,9*S*,10*S*,10a*R*)-9,10-Dihydroxy-hexahydrocannabinol, Cannabiripsol, Cannabiripsol-C₅, (-)-6a,7,10a-Trihydroxy-Δ⁹-tetrahydrocannabinol (-)-Cannabitetrol, 10-Oxo-Δ^{6a(10a)}-tetrahydrocannabinol OTHC); (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoin CBE-C₅, (5a*S*,6*S*,9*R*,9a*R*)-C₃-Cannabielsoin CBE-C₃, (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoic acid A CBEA-C₅ A, (5a*S*,6*S*,9*R*,9a*R*)-Cannabielsoic acid B CBEA-C₅ B; (5a*S*,6*S*,9*R*,9a*R*)-C₃-Cannabielsoic

acid B CBEA-C₃ B, Cannabiglendol-C₃ OH-iso-HHCV-C₃, Dehydrocannabifuran DCBF-C₅, Cannabifuran CBF-C₅), (–)- Δ^7 -*trans*-(1*R*,3*R*,6*R*)-Isotetrahydrocannabinol, (±)- Δ^7 -1,2-*cis*-(1*R*,3*R*,6*S*/1*S*,3*S*,6*R*)-Isotetrahydrocannabivarin, (–)- Δ^7 -*trans*-(1*R*,3*R*,6*R*)-Isotetrahydrocannabivarin); (±)-(1*aS*,3*aR*,8*bR*,8*cR*)-Cannabicyclol CBL-C₅, (±)-(1*aS*,3*aR*,8*bR*,8*cR*)-Cannabicyclic acid A CBLA-C₅ A, (±)-(1*aS*,3*aR*,8*bR*,8*cR*)-Cannabicyclovarin CBLV-C₃; Cannabicitran CBT-C₅); Cannabichromanone CBCN-C₅, Cannabichromanone-C₃ CBCN-C₃, and Cannabicomaronone CBCON-C₅). In some embodiments, the compositions and formulations comprise at least 1% w/w, at least 2% w/w, at least 5% w/w, or at least 10% w/w of at least one phytocannabinoid compound. In some
 10 embodiments, the formulations or compositions comprise from 0.1% to 10% w/w, 1% to 10% w/w, 0.1% to 5% w/w, 1% to 5% w/w, 1% to 20% w/w, 5% to 10% w/w, 5% to 20% w/w, or 10% to 20% w/w of said at least one phytocannabinoid compound. In some preferred embodiments, the compositions contain less than 1%, 0.1% or 0.01% Tetrahydrocannabinol (THC). In some preferred embodiments, the NMIFAs and cannabinoid compounds are derived from different sources and
 15 combined to make the formulation.

In other preferred embodiments, the compositions and formulations of the present invention further comprise at least one terpenoid compound in addition to the NMIFAs. In some embodiments, the concentrates one or more cannabinoid compounds (in the combinations and w/w percentages described above) in combination with from 0.1%, 0.5%, 1%, 2%, 3% to
 20 about 5% or 10% of one or more of Alloaromadendrene, allyl hexanoate, benzaldehyde, (*Z*)- α -*cis*-bergamotene, (*Z*)- α -*trans*-bergamotene, β -bisabolol, *epi*- α -bisabolol, β -bisabolene, borneol (camphol), *cis*- γ -bisabolene, borneol acetate (bornyl acetate), α -cadinene, camphene, camphor, *cis*-carveol, caryophyllene (β -caryophyllene), α -humulene (α -caryophyllene), γ -cadinene, Δ -3-carene, caryophyllene oxide, 1,8-cineole, citral A, citral B, cinnamaldehyde, α -
 25 copaene (aglaiene), γ -curcumene, β -cymene, β -elemene, γ -elemene, ethyl decdienoate, ethyl maltol, ethyl propionate, ethylvanillin, eucalyptol, α -eudesmol, β -eudesmol, γ -eudesmol, eugenol, *cis*- β -farnesene ((*Z*)- β -farnesene), *trans*- α -farnesene, *trans*- β -farnesene, *trans*- γ -bisabolene, fenchone, fenchol (norbornanol, β -fenchol), geraniol, α -guaiene, guaiol, methyl anthranilate, methyl salicylate, 2-methyl-4-heptanone, 3-methyl-4-heptanone, hexyl acetate,
 30 ipsdienol, isoamyl acetate, lemenol, limonene, d-limonene (limonene), linolool (linalyl alcohol, β -linolool), α -longipinene, menthol, γ -muurolene, myrcene (β -myrcene), nerolidol, *trans*-nerolidol, nerol, β -ocimene (*cis*-ocimene), octyl acetate, α -phellandrene, phytol, α -pinene (2-pinene), β -pinene, pulegone, sabinene, *cis*-sabinene hydrate (*cis*-thujanol), β -selinene, α -selinene, γ -terpinene, terpinolene (isoterpine), terpineol (α terpineol), terpineol-4-

ol, α -terpinene (terpilene), α -thujene (organene), vanillin, viridiflorene (ledene), and α -ylange.

In still other preferred embodiments, the compositions and formulations of the present invention comprise one or more phytocannabinoids compounds and one or more terpenoid compounds, in the concentrations listed above, in addition to the NMIFAs.

It will be understood that the concentration ranges described above serve as guidance for the compositions and formulations. For example, the following formulations are within the scope of the present invention. In some particularly preferred embodiments, the NMIFA in the designated formulation is sciadonic acid.

Formulation 1	Formulation 2	Formulation 3	Formulation 4	Formulation 5
5% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	20% w/w NMIFA
0.5% w/w phytocannabinoid compounds	1.0% w/w phytocannabinoid compounds	2.0% w/w phytocannabinoid compounds	0.1% w/w phytocannabinoid compounds	2.0% w/w phytocannabinoid compounds
94.5% w/w other components	89% w/w other components	88% w/w other components	89.9% w/w other components	78% other components

10

Formulation 6	Formulation 7	Formulation 8	Formulation 9	Formulation 10
5% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	20% w/w NMIFA
0.1% w/w terpenoid compounds	1.0% w/w terpenoid compounds	2.0% w/w phytocannabinoid compounds	0.1% w/w phytocannabinoid compounds	2.0% w/w phytocannabinoid compounds
94.5% w/w other components	89% w/w other components	0.1% w/w terpenoid compounds	1.0% w/w terpenoid compounds	2.0% w/w terpenoid compounds
		87.9% w/w other components	88.9% w/w other components	76% other components

Formulation 11	Formulation 12	Formulation 13	Formulation 14	Formulation 15
5% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	20% w/w NMIFA
60% w/w hemp or cannabis	80% w/w hemp or cannabis	85% w/w hemp or cannabis	40% w/w hemp or cannabis	70% w/w hemp or cannabis

extract containing CBD	extract containing CBD	extract containing CBD	extract containing CBD	extract containing CBD
35% w/w other components	10% w/w other components	5% w/w other components	50% w/w other components	10% other components

Formulation 16	Formulation 17	Formulation 18	Formulation 19	Formulation 20
5% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	10% w/w NMIFA	20% w/w NMIFA
60% w/w CBD	80% w/w CBD	85% w/w CBD	25% w/w CBD	70% w/w CBD
35% w/w other components	10% w/w other components	5% w/w other components	65% w/w other components	10% other components

It will be understood that the NMIFAs may be provided in the formulation as free fatty acids, as ethyl esters, or in the form of diglycerides, triglycerides, or phospholipids to which the NMIFA is attached. The formulations are preferably characterized by comprising a particular ratio of the bioactive fatty acids to one another or as having a defined weight/weight (w/w) percentage of the bioactive fatty acids which refers to the weight of the specific fatty acid per total weight of fatty acids in the formulation (i.e., grams the specified acid per 100 grams of fatty acids in the lipid formulation).

Thus, the formulations according to the present technology include phytocannabinoids and fatty acids analogous to naturally occurring fatty acids, especially NMIFAs or their analogs, alone in combination with other short and/or medium chain fatty acids, or naturally occurring lipids comprising the fatty acids. Incorporation of the fatty acids in naturally occurring lipids (e.g., monoglycerides, diglycerides, triglycerides, and/or phospholipids) produces a compound with different absorption characteristics compared to free fatty acids. In addition, it is contemplated that incorporating fatty acids in naturally occurring lipids (e.g., monoglycerides, diglycerides, triglycerides, and/or phospholipids) may also increase the bioavailability or stability.

In some embodiments, the NMIFAs in the formulation are esterified to a triglyceride, diglyceride, monoglyceride or phospholipid molecule. In some embodiments, the fatty acids in the lipid formulation are provided as ethyl esters. In some embodiments, structured esters or lipids are provided such as structured esters, diglycerides, triglycerides or phospholipids wherein at least one ester linkage in the structured ester, diglyceride, triglyceride or phospholipid contains a short chain or medium chain fatty acid and least one other ester linkage in the structured ester, diglyceride, triglyceride or phospholipid contains an NMIFA.

In some embodiments, the fatty acids in the formulations are provided by blending one or more oils or lipids. In some embodiments, the NMIFAs and phytocannabinoids are provided from one or more natural sources as described above.

5 In some embodiments, the formulations are suitable for human consumption on a daily basis for an extended period of time, e.g., 1 month, 2 months, 6 months, 1 year or 2 years, when provided in daily dosage of from 200 mg to 5 or 10 grams. In some embodiments, the lipid formulations further comprise a food safe antioxidant. In some embodiments, the lipid formulations are provided in an oral delivery vehicle, food product, nutritional supplement, dietary supplement or functional food.

10 The present invention likewise provides methods of using the formulations. These methods and uses are described in detail below but may be summarized as follows. In some embodiments, the present invention provides methods of treating a subject suffering from inflammation comprising administering to the subject the bioactive lipid and non-fatty acid ant-inflammatory drug formulation/s or oral delivery vehicle/s, food product, nutritional supplement, dietary supplement or functional food comprising the lipid formulation to a subject in need thereof. In some embodiments,
15 the administration is oral, topical, parenteral, enteral, transdermal, intradermal, intraocular, intravitreal, sublingual, or intravaginal and may preferably comprise an effective amount of the composition.

In some preferred embodiments, the present invention provides methods of increasing ketogenesis, decreasing appetite, suppressing appetite, decreasing food or caloric intake, in a subject
20 in need thereof (e.g., an overweight or obese subject or subject desiring to lose weight). Accordingly, in some preferred embodiments, the compositions and formulations of the present invention are utilized as anorectic agents. In other preferred embodiments, the compositions and formulations of the present invention are utilized to assist in weight management in a subject in need thereof (e.g., an overweight or obese subject or subject desiring to lose weight). In some embodiments, the
25 formulations and compositions of the present invention are utilized to improve body composition in a subject in need thereof. An improvement in body composition as used herein refers to an increase in the ratio of muscle to fat, or a decrease in the overall fat content of the body. In still other embodiments, the compositions and formulations of the present invention are administered to a subject in need thereof to treat (e.g., ameliorate, improve, normalize, increase or decrease as needed))
30 one or more symptoms associated with the following diseases or conditions: metabolic syndrome, diabetes 2, insulin resistance, blood sugar levels, and obesity. In still other preferred embodiments, the compositions and formulations of the present invention are utilized to improve gut health in a subject in need thereof and may be used to treat one or more symptoms of diseases or conditions including, but not limited to, Crohn's disease, irritable bowel syndrome (IBS), gluten intolerance,
35 celiac disease, leaky gut, acid reflux, Gastroesophageal Reflux Disease (GERD), gallstones, ulcerative colitis, and diverticulitis.

In further preferred embodiments, the present invention provides methods of reducing inflammation and/or alleviating or improving one or more of the following diseases or conditions: restenosis, arteriosclerosis, coronary heart disease, thrombosis, myocardial infarction, stroke, hypertension, fatty liver, diabetes, hyperglycemia, hyperinsulinemia, and stenosis, rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), inflammatory bowel diseases and colitis (e.g., Crohn's colitis), nephritis, various inflammatory skin disorders (e.g. psoriasis, atopic dermatitis and food allergy) and acute and chronic allograft rejection after organ transplantation, comprising administering to a subject in need thereof the formulation, food product, nutritional supplement, dietary supplement or function food as described above. In some embodiments, the administration or oral, topical, parenteral, enteral, transdermal, intradermal, intraocular, intravitreal, sublingual, or intravaginal and may preferably comprise an effective amount of the composition. The treatment is preferably performed under conditions such that the disease or condition is alleviated or improved as compared to an untreated state.

Provided herein are pharmaceutical formulations comprising a therapeutically effective amount of a composition according to the present technology and a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof). In some preferred embodiments, the NMIFA and phytocannabinoid compounds such as CBD (or hemp or cannabis extract) are formulated in the same delivery vehicle (e.g., a soft gel capsule) while in other embodiments, the NMIFA and cannabinoid compounds are provided in separate delivery vehicles. In some embodiments, oral delivery vehicles of the present invention provides from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg CBD and from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg NMIFA. Where the formulation is a topical formulation such as a lotion, cream, serum, oil or the like, the NMIFA and phytocannabinoids are preferably included so that a daily dosage of the topical formulation provides delivery of from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg CBD and from 1 to 1500 mg, from 2 to 100 mg, from 5 to 500 mg or from 20 to 200 mg NMIFA.

A composition according to the technology comprises or consists of a therapeutically effective amount of a pharmaceutically active agent as described above. In some embodiments, it includes a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof). Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient, or diluent is selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).

This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.

Pharmaceutical compositions within the scope of the present technology may include one or more of the following: preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, odorants, and/or salts. Compounds of the present technology may themselves be provided in the form of a pharmaceutically acceptable salt. In addition, embodiments may comprise buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients, and/or diluents. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.

They may also contain other therapeutically active agents in addition to compounds of the present technology. Where two or more therapeutic agents are used, they may be administered separately (e.g., at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus, combination therapy is within the scope of the present technology.

The routes for administration (delivery) include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestible solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, via the penis, vaginal, epidural, sublingual.

It is to be understood that not all of the agent need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.

If the agent of the present technology is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly, or subcutaneously administering the agent; and/or by using infusion techniques.

In some embodiments, pharmaceutical compositions adapted for oral administration are provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions. Tablets or hard gelatin capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Soft gelatin capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars. For the preparation of suspensions, oils (e.g., vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions. An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl

monostearate or glyceryl distearate may be used). Thus, the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.

Alternatively, the agent of the present technology can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The agent of the present technology may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin, the agent of the present technology can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

If the agent of the present technology is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.

For parenteral administration, the agent is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of that compound; the age, body weight, general health, sex, diet, mode and time of administration; rate of excretion; drug combination; the severity of the particular condition; and the individual undergoing therapy. The agent and/or the pharmaceutical composition of the present technology may be administered in accordance with a

regimen of from 1 to 10 times per day, such as once or twice per day. For oral and parenteral administration to human patients, the daily dosage level of the agent may be in single or divided doses.

Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg or from 0.1 to 1 mg/kg body weight. Naturally, the dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

“Therapeutically effective amount” refers to the amount of the therapeutic agent that is effective to achieve its intended purpose, i.e., reduction of inflammation and associated symptoms.

While individual patient needs may vary, determination of optimal ranges for effective amounts of the compounds related to the technology is within the skill of the art. Generally, the dosage regimen for treating a condition with the compounds and/or compositions of this technology is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient; the severity of the dysfunction; the route of administration; pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used; whether a drug delivery system is used; and whether the compound is administered as part of a drug combination and can be adjusted by one skilled in the art. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the exemplary dosage regimens set forth herein.

All publications and patents mentioned in the above specification are herein incorporated by reference in their entirety for all purposes. Various modifications and variations of the described compositions, methods, and uses of the technology will be apparent to those skilled in the art without departing from the scope and spirit of the technology as described. Although the technology has been described in connection with specific exemplary embodiments, it should be understood that the technology as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the technology that are obvious to those skilled in pharmacology, biochemistry, medical science, or related fields are intended to be within the scope of the following claims.

CLAIMS

WE CLAIM:

- 5 1. A formulation comprising at least 1% w/w non-methylene interrupted fatty acids (NMIFAs) and a Cannabis or hemp extract comprising cannabidiol.
2. The formulation of claim 1, further comprising at least 2% w/w, at least 5% w/w, at least 10% w/w, or at least 20% w/w of said NMIFAs.
- 10 3. The formulation of any one of claims 1 to 2, further comprising from 1% to 10% w/w, 1% to 20% w/w, 1% to 30% w/w, 5% to 10% w/w, 5% to 20% w/w, or 5% to 30% w/w of said NMIFAs.
4. The formulation of any one of claims 1 to 3, wherein said NMIFAs are selected from the
15 group consisting of sciadonic acid, juniperonic acid, pinolenic acid, dihomopinolenic acid, coniferonic acid (5,9,12,15 18:4) and synthetic fatty acids selected from the group consisting of 1, 11, 14, 17 20:4; 2, 11, 14, 17 20:4; 3, 11, 14 17 20:4; 4, 11, 14 17 20:4; 6, 11,14 17 20:4; 7,11,14 17 20:4; 1, 9, 12, 15 18:4; 2, 9, 12, 15 18:4; 3, 9, 12, 15 18:4; 4, 9, 12, 15 18:4; 5, 9, 12, 15 18:4; 1, 11, 14 20:3; 2, 11, 14 20:3; 3, 11, 14 20:3; 4, 11, 14 20:3; 6, 11,14 20:3; 1, 9, 12 18:3; 2, 9, 12 18:3; 3, 9, 12 18:3; and 4, 9,
20 12 18:3 fatty acids.
5. The formulation of any one of claims 1 to 4, wherein said NMIFAs are provided as a structured ester, diglyceride, triglyceride or phospholipid wherein at least one ester linkage in said ester, diglyceride, triglyceride or phospholipid contains an NMIFA.
- 25 6. The formulation of any one of claims 1 to 5, further comprising at least 2% w/w, at least 5% w/w, at least 10% w/w, at least 20% w/w, or at least 50% w/w of said Cannabis or hemp extract comprising cannabidiol.
- 30 7. The formulation of any one of claims 1 to 6, further comprising from 1% to 90% w/w, 10% to 90% w/w, 20% to 90% w/w, 30% to 90% w/w, 40% to 90% w/w, or 50% to 90% w/w cannabidiol.
8. The formulation of any one of claims 1 to 7, wherein said Cannabis or hemp extract comprising cannabidiol has a cannabidiol concentration of from about 10% to 100% w/w cannabidiol,
35 20% to 90% w/w cannabidiol, or 20% to 60% w/w cannabidiol.
9. An oral delivery vehicle comprising the formulation of any one of claims 1 to 8.

10. The oral delivery vehicle of claim 9, wherein said oral delivery vehicle is selected from the group consisting of a capsule, gel capsule, soft gel capsule and syrup.

11. The oral delivery vehicle of any one of claims 9 to 10, further comprising a flavoring agent and/or antioxidant not naturally occurring with said NMIFA and/or said at least one phytocannabinoid compound.

12. A method of reducing or treating inflammation in a subject in thereof comprising administering an effective amount of a formulation or oral delivery vehicle as defined in any one of claims 1 to 11.

13. Formulation or oral delivery vehicle as defined in any one of claims 1 to 11 for use to reduce or treat inflammation in a subject in need thereof.

14. The method of claim 12 or use of claim 13, wherein said inflammation is caused by or associated with a disease or condition selected from the group consisting of restenosis, arteriosclerosis, coronary heart disease, thrombosis, myocardial infarction, stroke, hypertension, fatty liver, diabetes, hyperglycemia, hyperinsulinemia, and stenosis, rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), inflammatory bowel diseases and colitis (e.g., Crohn's colitis), nephritis, various inflammatory skin disorders (e.g. psoriasis, atopic dermatitis and food allergy) and acute and chronic allograft rejection after organ transplantation.

15. Formulation or oral delivery vehicle as defined in any one of claims 1 to 11 for use to reduce or treat pain in a subject in need thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/59201

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A01H 6/28; A61K 31/202, 31/352 (2019.01)

CPC - A01H 6/28; A61K 31/202, 31/352

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2018/118197 A1 (POSTREL, R) 28 June 2018; page 21, lines 7-23; page 25, lines 21-23; page 26, lines 14-15; claims 9, 27	1-2, 3/1-2
Y	WO 2018/017667 A1 (SCIADONIC, INC.) 25 January 2018; page 2, lines 6-23; page 5, lines 17-19	1-2, 3/1-2
A	US 2007/0104805 A1 (UDELL, RG) 10 May 2007; entire document	1-2, 3/1-2

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 December 2019 (22.12.2019)

Date of mailing of the international search report

22 JAN 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/59201

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 4-15
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.